CV Sciences (CVSI) Amortizatization of Intangibles (2013 - 2026)
CV Sciences (CVSI) reported Amortizatization of Intangibles of $91000.0 for Q1 2026, down 38.93% on a YoY basis from $149000.0 in Q1 2025, and down 28.35% sequentially from $127000.0 in Q4 2025.
CV Sciences (CVSI) Amortizatization of Intangibles (2013 - 2026) Analysis & Trends
CV Sciences (CVSI) has 8 years of Amortizatization of Intangibles data on file, last reported at $91000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 38.93% year-over-year to $91000.0; the trailing twelve-month figure through Mar 2026 stood at $455000.0 (up 27.09% YoY), and the FY2025 full-year result was $513000.0, up 145.45% from the prior year.
- Amortizatization of Intangibles retreated to $91000.0 in Q1 2026, from $127000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $149000.0 in Q1 2025 to a low of $91000.0 in Q1 2026.
- A 3-year average of $116142.9 and a median of $117000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles soared 38.04% in 2025 and slumped 38.93% in 2026, its largest moves.
- Tracing CVSI's Amortizatization of Intangibles over 3 years: stood at $92000.0 in 2024, then jumped by 38.04% to $127000.0 in 2025, then retreated by 28.35% to $91000.0 in 2026.
- Business Quant data shows CVSI's Amortizatization of Intangibles at $91000.0 in Q1 2026, $127000.0 in Q4 2025, and $107000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | 91,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91,000.00 |
| Mar 31, 2026 | 91,000.00 |
| Dec 31, 2025 | 127,000.00 |
| Dec 31, 2025 | 127,000.00 |
| Sep 30, 2025 | 107,000.00 |
| Sep 30, 2025 | 107,000.00 |
| Jun 30, 2025 | 130,000.00 |
| Jun 30, 2025 | 130,000.00 |
| Mar 31, 2025 | 149,000.00 |
| Mar 31, 2025 | 149,000.00 |
| Dec 31, 2024 | 92,000.00 |
| Dec 31, 2024 | 92,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Jun 30, 2018 | 37,000.00 |
| Jun 30, 2018 | 37,000.00 |
| Mar 31, 2018 | 13,000.00 |
| Mar 31, 2018 | 13,000.00 |
| Sep 30, 2017 | 10,988.00 |
| Sep 30, 2017 | 10,988.00 |